Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer

9 Mar 2022

Abstract excerpt

Major advances have been made in CRC treatment in recent years, especially in molecularly driven therapies and immunotherapy. Despite this, a large number of advanced colorectal cancer patients do not benefit from these treatments and their prognosis remains poor. The landscape of DNA damage response (DDR) alterations is emerging as a novel target for treatment in different cancer types. PARP inhibitors have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35326540
DOI: 10.3390/cancers14061388

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal CancerPMID 35326540Read ↗

Advances in DNA damage response inhibitors in colorectal cancer therapySemantic proximity Read ↗

Exploiting DNA repair defects in colorectal cancerSemantic proximity Read ↗

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP InhibitorsSemantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response in CancerSemantic proximity Read ↗

DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errorsSemantic proximity Read ↗

Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical PerspectivesSemantic proximity Read ↗

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionSemantic proximity Read ↗

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal CancerSemantic proximity Read ↗

PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinationsSemantic proximity Read ↗

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic ImplicationsSemantic proximity Read ↗

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapySemantic proximity Read ↗

Targeting DNA repair pathway in cancer: Mechanisms and clinical applicationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.